Nov 16, 2018

Chugai Files Lawsuit against Alexion for Infringement of its Proprietary Antibody Engineering Technology in the U.S.

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (1st Section of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Tatsuro Kosaka
Inquiries to: Masahiko Uchida,
General Manager, Corporate Communications Dept.

Chugai Pharmaceutical Co., Ltd. announced today that it has filed a patent infringement lawsuit in the United States District Court for the District of Delaware as follows.

  1. Date of Complaint
    November 15, 2018 (local time)
  2. Reasons for the Action
    Chugai alleges that the anti-C5 antibody ALXN1210 (ravulizumab) product, an investigational drug developed by Alexion Pharmaceuticals, Inc., infringes one of its U.S. patents (U.S. Patent No. 9,890,377) relating to its proprietary antibody engineering technology. Thus, Chugai filed a patent infringement lawsuit against Alexion requesting a judgment that the ALXN1210 product infringes Chugai’s U.S. patent and injunctive relief precluding manufacturing and selling of the ALXN1210 product within the U.S.
  3. Defendant
    1. Name:
      Alexion Pharmaceuticals, Inc.
    2. Address:
      121 Seaport Blvd., Boston, Massachusetts, 02210, USA
  4. Prospects
    No changes are expected to be made to Chugai’s financial prospects at this point.


  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail:
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail:
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top